This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tappe, D.
Right arrow Articles by Frosch, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tappe, D.
Right arrow Articles by Frosch, M.

Next Article 

Clinical and Vaccine Immunology, November 2008, p. 1633-1637, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00272-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of a Commercial Echinococcus Western Blot Assay for Serological Follow-Up of Patients with Alveolar Echinococcosis {triangledown}

Dennis Tappe,1* Beate Grüner,2 Peter Kern,2 and Matthias Frosch1

Institute of Hygiene and Microbiology, University of Würzburg, Würzburg, Germany,1 Comprehensive Infectious Diseases Center, Division of Infectiology and Clinical Immunology, University Hospital and Medical Center Ulm, Ulm, Germany2

Received 20 July 2008/ Returned for modification 27 August 2008/ Accepted 8 September 2008

A total of 20 patients with alveolar echinococcosis in different clinical stages according to the WHO-PNM staging system (P, parasitic mass in the liver; N, involvement of neighboring organs; M, metastasis) were followed up serologically with the commercial Echinococcus Western Blot IgG assay and a crude antigen extract enzyme-linked immunosorbent assay (ELISA). The cohort included patients after curative resection and patients who had unresectable lesions with stable disease or progressive infection. There were visible correlations of the crude antigen ELISA index and the presence and intensity of diagnostic bands in the Western blot. In most patients after curative resection, bands at 7, 16, and 18 kDa markedly decreased or vanished after 1 to 4 years. In a patient with a nonviable lesion (it died out), bands at 16 and 18 kDa vanished after 4 years. Among individuals with unresectable lesions but stable disease under antiparasitic chemotherapy, a decrease of all diagnostic bands was visible after 2 to 3 years in half of the patients, whereas the other half had unchanged blot results after 4 to 6 years. Patients with progressive disease showed increasing intensities of bands at 16, 18, and 7 kDa. The change of banding patterns was not influenced by the PNM stage in patients after curative surgery or with unresectable lesions. Our data indicate a correlation of the 7-, 16-, and 18-kDa-Western blot bands with disease activity independent of the PNM stage. This study demonstrated the usefulness of the Echinococcus Western Blot IgG assay as an additional serological test for the follow-up of patients with alveolar echinococcosis.


* Corresponding author. Mailing address: Institute of Hygiene and Microbiology, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. Phone: 0049-931-201-46036. Fax: 0049-931-201-46445. E-mail: dtappe{at}hygiene.uni-wuerzburg.de

{triangledown} Published ahead of print on 17 September 2008.


Clinical and Vaccine Immunology, November 2008, p. 1633-1637, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00272-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Stensvold, C. R., Skov, J., Moller, L. N., Jensen, P. M., Kapel, C. M. O., Petersen, E., Nielsen, H. V. (2009). Seroprevalence of Human Toxocariasis in Denmark. CVI 16: 1372-1373 [Abstract] [Full Text]